Skip to content

Thin Bronchoscope and Virtual Bronchoscopic Navigation System for Tuberculosis

Thin Bronchoscope and Virtual Bronchoscopic Navigation System for Rapid Detection of Mycobacterium Tuberculosis and Resistant-conferring Mutations

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03802812
Enrollment
88
Registered
2019-01-14
Start date
2019-02-01
Completion date
2022-04-19
Last updated
2022-04-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tuberculosis

Brief summary

This study investigates the utility of thin bronchoscope and virtual bronchoscopic navigation system (targeted bronchial washing) for detection of M. tuberculosis and resistant-conferring mutations in patients with pulmonary tuberculosis. Time to appropriate treatment and stain/culture conversion are also evaluated.

Detailed description

Comparisons of detection rate of M. tuberculosis and resistant-conferring mutations between patients who perform CT-guided conventional bronchoscope and patients who perform VBN-guided thin bronchoscope.

Interventions

DEVICEThin bronchoscope and VBN

targeted washing at more adjacent TB lesion using thin bronchoscope and virtual bronchoscopic navigation system

Sponsors

Pusan National University Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
No

Inclusion criteria

* age of 18 or more * persons who are suspected with pulmonary tuberculosis on radiologic examination * persons who cannot spit sputum or persons with negative results on sputum AFB smear and TB-PCR or Xpert MTB/RIF assay

Exclusion criteria

* persons who do not agree with bronchoscopy (persons who want empirical treatment for TB) * persons with contraindications for bronchoscopy * bleeding tendency * uncontrolled respiratory disease (hypoxemia) * uncontrolled cardiovascular disease

Design outcomes

Primary

MeasureTime frameDescription
detection of M. tuberculosis and resistant-conferring mutations2months after procedureevaulation by sensitivity, specificity, PPV and NPV

Secondary

MeasureTime frameDescription
time to appropriate treatment and stain/culture conversion6months after proceduredate of treatment initiation and stain/culture negative conversion

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 11, 2026